Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units

American Journal of Infection Control

Volumn 42, Issue 6, 2014, Pages 626-631

  Patel, Sameer J ^a   Oliveira, André P ^a   Zhou, Juyan Julia ^a   Alba, Luis ^a   Furuya, E Yoko ^a,b   Weisenberg, Scott A ^c   Jia, Haomiao ^a,d   Clock, Sarah A ^a   Kubin, Christine J ^a,b   Jenkins, Stephen G ^e   Schuetz, Audrey N ^b,e   Behta, Maryam ^f   Della Latta, Phyllis ^a   Whittier, Susan ^a   Rhee, Kyu ^e   Saiman, Lisa ^a,b  

^a Department of Medicine   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Summitt Medical Center   (United States)

^d Department of Medicine   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibiotic resistance; Gram negative bacteria; Health care associated infection; Mortality

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CASE CONTROL STUDY; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; EXPOSURE; EXTREMELY DRUG RESISTANT GRAM NEGATIVE BACILLUS; EXTREMELY DRUG RESISTANT GRAM NEGATIVE INFECTION; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GROUPS BY AGE; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MECHANICAL VENTILATOR; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; SURVIVAL; URINARY CATHETER; ACINETOBACTER INFECTION; ADOLESCENT; AGE; CROSS INFECTION; KLEBSIELLA INFECTION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PSEUDOMONAS INFECTION; RISK FACTOR; TIME;

ACINETOBACTER INFECTIONS; ADOLESCENT; AGE FACTORS; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LEVOFLOXACIN; LIVER DISEASES; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; TIME FACTORS;

EID: 84901241043     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2014.01.027     Document Type: Article

References (37)

1. E. Lautenbach, and R.E. Polk Resistant gram-negative bacilli: a neglected healthcare crisis? Am J Health Syst Pharm 64 2007 S3 21
2. G. Patel, S. Huprikar, S.H. Factor, S.G. Jenkins, and D.P. Calfee Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies Infect Control Hosp Epidemiol 29 2008 1099 1106
3. C.G. Giske, D.L. Monnet, O. Cars, and Y. Carmeli Clinical and economic impact of common multidrug-resistant gram-negative bacilli Antimicrob Agents Chemother 52 2008 813 821
4. M.E. Falagas, and I.A. Bliziotis Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29 2007 630 636
5. T.C. Horan, M. Andrus, and M.A. Dudeck CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting Am J Infect Control 36 2008 309 332
6. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 17th informational supplement. M100-S17 2007 Clinical and Laboratory Standards Institute Wayne [PA]
7. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 18th informational supplement. M100-S18 2008 Clinical and Laboratory Standards Institute Wayne [PA]
8. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 19th informational supplement. M100-S19 2009 Clinical and Laboratory Standards Institute Wayne [PA]
9. E.L. Larson, B. Cohen, B. Ross, and M. Behta Isolation precautions for methicillin-resistant Staphylococcus aureus: electronic surveillance to monitor adherence Am J Crit Care 19 2010 16 26
10. W.A. Knaus, D.P. Wagner, E.A. Draper, J.E. Zimmerman, M. Bergner, and P.G. Bastos et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults Chest 100 1991 1619 1636
11. N. Safdar, and D.G. Maki The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida Ann Intern Med 136 2002 834 844
12. L.B. Gasink, P.H. Edelstein, E. Lautenbach, M. Synnestvedt, and N.O. Fishman Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K pneumoniae Infect Control Hosp Epidemiol 30 2009 1180 1185
13. S. Le Hello, V. Falcot, F. Lacassin, M. Mikulski, and F. Baumann Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific Scand J Infect Dis 42 2010 821 826
14. A.D. Harris, D. Smith, J.A. Johnson, D.D. Bradham, and M.C. Roghmann Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients Clin Infect Dis 34 2002 340 345
15. C.M. Fortaleza, M.P. Freire, C. Filho Dde, and M. de Carvalho Ramos Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil Infect Control Hosp Epidemiol 27 2006 901 906
16. S.R. Ansari, H. Hanna, R. Hachem, Y. Jiang, K. Rolston, and I. Raad Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer Cancer 109 2007 2615 2622
17. E.L. van der Veen, A.G. Schilder, T.K. Timmers, M.M. Rovers, A.C. Fluit, and M.J. Bonten et al. Effect of long-term trimethoprim/sulfamethoxazole treatment on resistance and integron prevalence in the intestinal flora: a randomized, double-blind, placebo-controlled trial in children J Antimicrob Chemother 63 2009 1011 1016
18. P.D. Brown, A. Freeman, and B. Foxman Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan Clin Infect Dis 34 2002 1061 1066
19. M. Halwani, M. Solaymani-Dodaran, H. Grundmann, C. Coupland, and R. Slack Cross-transmission of nosocomial pathogens in an adult intensive care unit: incidence and risk factors J Hosp Infect 63 2006 39 46
20. T.E. Zaoutis, M. Goyal, J.H. Chu, J.H. Chu, S.E. Coffin, and L.M. Bell et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in children Pediatrics 115 2005 942 949
21. V.G. Alexiou, A. Michalopoulos, G.C. Makris, G. Peppas, G. Samonis, and M.E. Falagas Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study Eur J Clin Microbiol Infect Dis 31 2012 557 566
22. S. Nseir, C. Di Pompeo, M. Diarra, H. Brisson, S. Tissier, and M. Buolo et al. Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study Crit Care Med 35 2007 1318 1323
23. M.E. Falagas, P.K. Koletsi, and I.A. Bliziotis The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa J Med Microbiol 55 2006 1619 1629
24. M.E. Falagas, and D.E. Karageorgopoulos Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology Clin Infect Dis 46 2008 1121 1132
25. A.J. Ray, C.K. Hoyen, T.F. Taub, E.C. Eckstein, and C.J. Donskey Nosocomial transmission of vancomycin-resistant enterococci from surfaces JAMA 287 2002 1400 1411
26. V. Aloush, S. Navon-Venezia, Y. Seigman-Igra, S. Cabili, and Y. Carmeli Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact Antimicrob Agents Chemother 50 2006 43 48
27. C. Gudiol, F. Tubau, L. Calatayud, C. Garcia-Vidal, M. Cisnal, and I. Sánchez-Ortega et al. Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes J Antimicrob Chemother 66 2011 657 663
28. D.C. Lye, A. Earnest, M.L. Ling, T.E. Lee, H.C. Yong, and D.A. Fisher et al. The impact of multidrug resistance in healthcare-associated and nosocomial gram-negative bacteraemia on mortality and length of stay: cohort study Clin Microbiol Infect 18 2012 502 508
29. M. Nguyen, G.A. Eschenauer, M. Bryan, K. O'Neil, E.Y. Furuya, and P. Della-Latta et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes Diagn Microbiol Infect Dis 67 2010 180 184
30. G. Peralta, M.B. Sanchez, J.C. Garrido, I. De Benito, M.E. Cano, and L. Martínez-Martínez et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia J Antimicrob Chemother 60 2007 855 863
31. T.P. Lodise, N. Patel, A. Kwa, J. Graves, J.P. Furuno, and E. Graffunder et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection Antimicrob Agents Chemother 51 2007 3510 3515
32. M. Manikal Vivek, D. Landman, G. Saurina, E. Oydna, H. Lal, and J. Quale Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage Clin Infect Dis 31 2000 101 106
33. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
34. M. Klompas Does this patient have ventilator-associated pneumonia? JAMA 297 2007 1583 1593
35. J.L. Marsh, J.L. Hutton, and K. Binks Removal of radiation dose response effects: an example of over-matching BMJ 325 2002 327 330
36. A.D. Harris, M.H. Samore, M. Lipsitch, K.S. Kaye, E. Perencevich, and Y. Carmeli Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli Clin Infect Dis 34 2002 1558 1563
37. J.J. Zhou, S.J. Patel, H. Jia, S.A. Weisenberg, E.Y. Furuya, and C.J. Kubin et al. Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care unit Infect Control Hosp Epidemiol 34 2013 274 283